Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%

Axogen, Inc.

2025-FY EPS reported -$0.34 revenue$225,208,000

Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
FY2025 revenue $225.2M (+20.2% YoY); adjusted net income $14.4M ($0.29/sh); adjusted EBITDA $27.9M.
FDA approved Avance BLA on Dec 3, 2025; CMS new Level 3 code raises Avance facility reimbursement 40% to $8,965.
Closed upsized public offering of 4.6M shares for $133.3M net; $69.7M used to repay Oberland loan facility.
2026 guidance: revenue at least $265.7M (+18% YoY); gross margin 74%-76%; expects positive free cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.